Hexian Li

700 total citations · 1 hit paper
23 papers, 477 citations indexed

About

Hexian Li is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, Hexian Li has authored 23 papers receiving a total of 477 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 10 papers in Immunology and 8 papers in Molecular Biology. Recurrent topics in Hexian Li's work include CAR-T cell therapy research (12 papers), Virus-based gene therapy research (4 papers) and Viral Infectious Diseases and Gene Expression in Insects (4 papers). Hexian Li is often cited by papers focused on CAR-T cell therapy research (12 papers), Virus-based gene therapy research (4 papers) and Viral Infectious Diseases and Gene Expression in Insects (4 papers). Hexian Li collaborates with scholars based in China and New Zealand. Hexian Li's co-authors include Aiping Tong, Ying Zhou, Zongliang Zhang, Qizhong Lu, Meijun Zheng, Kunhong Zhong, Zeng Wang, Guoqing Wang, Xin Tang and Liangxue Zhou and has published in prestigious journals such as Journal of Controlled Release, Frontiers in Immunology and Gene.

In The Last Decade

Hexian Li

21 papers receiving 474 citations

Hit Papers

CXCL11-armed oncolytic adenoviruses enhance CAR-T cell th... 2022 2026 2023 2024 2022 40 80 120

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Hexian Li China 12 234 124 120 97 64 23 477
Ken‐Edwin Aryee United States 6 189 0.8× 157 1.3× 214 1.8× 102 1.1× 50 0.8× 13 560
Firas Hamdan Finland 11 216 0.9× 160 1.3× 171 1.4× 93 1.0× 92 1.4× 20 453
Paul Castillo United States 9 331 1.4× 130 1.0× 154 1.3× 100 1.0× 130 2.0× 34 462
Francesco Nannini United Kingdom 6 188 0.8× 111 0.9× 123 1.0× 59 0.6× 76 1.2× 8 327
Jason E. Ekert United States 9 143 0.6× 155 1.3× 89 0.7× 77 0.8× 114 1.8× 13 519
Luis A. Rojas Spain 12 250 1.1× 210 1.7× 72 0.6× 238 2.5× 40 0.6× 19 429
Thomas Poiret Sweden 14 327 1.4× 113 0.9× 312 2.6× 63 0.6× 54 0.8× 30 656
Xiang Ao China 12 196 0.8× 237 1.9× 159 1.3× 75 0.8× 57 0.9× 17 533
Thomas Shum United States 10 476 2.0× 172 1.4× 198 1.6× 177 1.8× 161 2.5× 17 612
R. Alejandro Sica United States 11 181 0.8× 133 1.1× 110 0.9× 34 0.4× 21 0.3× 39 428

Countries citing papers authored by Hexian Li

Since Specialization
Citations

This map shows the geographic impact of Hexian Li's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hexian Li with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hexian Li more than expected).

Fields of papers citing papers by Hexian Li

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hexian Li. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hexian Li. The network helps show where Hexian Li may publish in the future.

Co-authorship network of co-authors of Hexian Li

This figure shows the co-authorship network connecting the top 25 collaborators of Hexian Li. A scholar is included among the top collaborators of Hexian Li based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hexian Li. Hexian Li is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Li, Hexian, Qizhong Lu, Zhengyu Yu, et al.. (2025). CRISPR/Cas9-engineered universal CD123/B7-H3 tandem CAR-T cell for the treatment of acute myeloid leukemia. Chinese Medical Journal. 139(5). 728–740.
2.
Zhu, Zhixiong, Shuqin Cao, Hanwen Li, et al.. (2025). Myeloid-derived suppressor cell-targeted virus-like particles synergistically activate innate immune response for cancer immunotherapy. Journal of Controlled Release. 381. 113603–113603. 4 indexed citations
4.
Zheng, Meijun, Yijun Dong, Jia Li, et al.. (2024). Development and Characterization of a Lysosome-Targeting SLC3A2/PD-L1 Bispecific Antibody–Drug Conjugate for Enhanced Antitumor Efficacy in Solid Tumors. Molecular Cancer Therapeutics. 24(2). 261–274. 3 indexed citations
5.
Zhang, Zongliang, Yongdong Chen, Long Xu, et al.. (2024). Improved antitumor effects elicited by an oncolytic HSV-1 expressing a novel B7H3nb/CD3 BsAb. Cancer Letters. 588. 216760–216760. 11 indexed citations
6.
Lu, Qizhong, Hexian Li, Zhixiong Zhu, et al.. (2024). Delivery of CD47-SIRPα checkpoint blocker by BCMA-directed UCAR-T cells enhances antitumor efficacy in multiple myeloma. Cancer Letters. 585. 216660–216660. 12 indexed citations
7.
Lu, Qizhong, et al.. (2024). BCMA/CD47-directed universal CAR-T cells exhibit excellent antitumor activity in multiple myeloma. Journal of Nanobiotechnology. 22(1). 279–279. 10 indexed citations
8.
Yu, Zhengyu, Hexian Li, Qizhong Lu, et al.. (2024). Fc receptor-like 5 (FCRL5)-directed CAR-T cells exhibit antitumor activity against multiple myeloma. Signal Transduction and Targeted Therapy. 9(1). 16–16. 13 indexed citations
9.
Zhang, Zongliang, Long Xu, Zeng Wang, et al.. (2024). Systemic delivery of oncolytic herpes virus using CAR-T cells enhances targeting of antitumor immuno-virotherapy. Cancer Immunology Immunotherapy. 73(9). 173–173. 12 indexed citations
10.
Zhu, Zhixiong, Hexian Li, Qizhong Lu, et al.. (2024). mRNA‐Engineered CD5‐CAR‐γδTCD5‐ Cells for the Immunotherapy of T‐Cell Acute Lymphoblastic Leukemia. Advanced Science. 11(35). e2400024–e2400024. 11 indexed citations
12.
Wang, Jieru, Hexian Li, Jing Xu, et al.. (2023). The chain mediation model of social support and life satisfaction among migrant older adults with children: The role of mental health and sleep quality. Archives of Gerontology and Geriatrics. 115. 105122–105122. 3 indexed citations
13.
Zhang, Zongliang, Guoqing Wang, Kunhong Zhong, et al.. (2023). A drug screening to identify novel combinatorial strategies for boosting cancer immunotherapy efficacy. Journal of Translational Medicine. 21(1). 23–23. 15 indexed citations
14.
Zhao, Shasha, Yuelong Wang, Min Mu, et al.. (2022). Genome-scale CRISPR–Cas9 screen reveals novel regulators of B7-H3 in tumor cells. Journal for ImmunoTherapy of Cancer. 10(6). e004875–e004875. 13 indexed citations
15.
Wang, Zeng, Kunhong Zhong, Guoqing Wang, et al.. (2022). Loss of furin site enhances SARS-CoV-2 spike protein pseudovirus infection. Gene. 856. 147144–147144. 8 indexed citations
16.
Wang, Guoqing, Zongliang Zhang, Kunhong Zhong, et al.. (2022). CXCL11-armed oncolytic adenoviruses enhance CAR-T cell therapeutic efficacy and reprogram tumor microenvironment in glioblastoma. Molecular Therapy. 31(1). 134–153. 140 indexed citations breakdown →
17.
Wang, Jieru, et al.. (2022). The effects of oral health and social support on health-related quality of life of migrant older with children in Weifang, China. BMC Public Health. 22(1). 1505–1505. 6 indexed citations
18.
Tang, Mei, Caili Chen, Guoqing Wang, et al.. (2022). Evaluation of B7-H3 Targeted Immunotherapy in a 3D Organoid Model of Craniopharyngioma. Biomolecules. 12(12). 1744–1744. 14 indexed citations
19.
Lu, Qizhong, Zongliang Zhang, Hexian Li, et al.. (2021). Development of multivalent nanobodies blocking SARS-CoV-2 infection by targeting RBD of spike protein. Journal of Nanobiotechnology. 19(1). 33–33. 59 indexed citations
20.
Zhou, Ying & Hexian Li. (2013). Analysis of a high‐rise steel structure with viscous damped outriggers. The Structural Design of Tall and Special Buildings. 23(13). 963–979. 62 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026